Figure 9. Diagram illustrating the pathway of our proposed hypothetical mechanism. DNMT3B reduces the levels of MMP3 and MMP9 and increases the levels of collagen II and aggrecan through the TRPA1-COX2-YAP axis. DNMT3B then reduces the ECM degradation of NP cells and the inflammatory response, thereby alleviating IVDD.